Jazz Pharmaceuticals will collaborate with Codiak BioSciences on the research, development and commercialization of exosome therapeutics to treat cancer.
With the deal, Massachusetts-based Codiak granted Jazz an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize therapeutic candidates directed at five targets to be developed using Codiak's engEx™ precision engineering platform for exosome therapeutics. This novel therapeutic approach has potential to provide transformational benefit to subgroup of patients with modulations in well validated but previously undruggable targets.
Codiak will receive $56M upfront, up to $200M in milestones per target and tiered mid-single-digit-to-high-teens royalties on net sales.
Read the press release
